Skip to main content

Mektovi Side Effects

Generic name: binimetinib

Medically reviewed by Last updated on May 18, 2024.

Note: This document contains side effect information about binimetinib. Some dosage forms listed on this page may not apply to the brand name Mektovi.

Applies to binimetinib: oral tablet.

Serious side effects of Mektovi

Along with its needed effects, binimetinib (the active ingredient contained in Mektovi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking binimetinib:

More common


Other side effects of Mektovi

Some side effects of binimetinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to binimetinib: oral tablet.


Very common (10% or more): Anemia (36%), hemorrhage (19%), leukopenia (13%), lymphoma (13%), neutropenia (13%)

Common (1% to 10%): Venous thromboembolism (VTE)[Ref]


Common (1% to 10%): Hypersensitivity[Ref]


Uncommon (0.1% to 1%): Rhabdomyolysis[Ref]


Very common (10% or more): Retinopathy (20%), visual impairment (20%)

Common (1% to 10%): Retinal detachment, macular edema, uveitis

Uncommon (0.1% to 1%): Retinal vein occlusion[Ref]


Very common (10% or more): Hyponatremia (18%), peripheral edema (13%)[Ref]


Very common (10% or more): Increased gamma glutamyl transferase (45%)

Common (1% to 10%): Alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased

Uncommon (0.1% to 1%): Alkaline phosphatase increased[Ref]


Uncommon (0.1% to 1%): Interstitial lung disease[Ref]


Very common (10% or more): Fatigue (43%), pyrexia (18%)[Ref]

Nervous system

Very common (10% or more): Dizziness (15%)[Ref]


Very common (10% or more): Increased creatinine (93%), increased creatine phosphokinase (58%)[Ref]


Very common (10% or more): Hypertension (11%)

Common (1% to 10%): Cardiomyopathy, fatal intracranial hemorrhage (in the setting of new or progressive brain metastases)[Ref]


Very common (10% or more): Rash (22%)

Common (1% to 10%): Panniculitis[Ref]


Very common (10% or more): Nausea (41%), diarrhea (36%), vomiting (30%), abdominal pain (28%), constipation (22%)

Common (1% to 10%): Rectal hemorrhage, hematochezia, hemorrhoidal hemorrhage, colitis[Ref]

Frequently asked questions


1. (2018) "Product Information. Mektovi (binimetinib)." Array BioPharma Inc.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.